Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 03:30 am
Share
Samil Pharmaceutical Co.,Ltd reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 1,543.58 million compared to KRW 1,070.32 million a year ago. Net loss was KRW 657.05 million compared to KRW 1,920.48 million a year ago. Basic loss per share from continuing operations was KRW 46 compared to KRW 138.1818 a year ago. Diluted loss per share from continuing operations was KRW 32 compared to KRW 134 a year ago. Basic loss per share was KRW 46 compared to KRW 152 a year ago. Diluted loss per share was KRW 32 compared to KRW 134 a year ago.
For the nine months, sales was KRW 4,143.87 million compared to KRW 2,960.54 million a year ago. Net income was KRW 769.43 million compared to net loss of KRW 1,858.78 million a year ago. Basic earnings per share from continuing operations was KRW 54 compared to basic loss per share from continuing operations of KRW 134.5455 a year ago. Diluted earnings per share from continuing operations was KRW 38 compared to diluted loss per share from continuing operations of KRW 126 a year ago. Basic earnings per share was KRW 54 compared to basic loss per share of KRW 148 a year ago. Diluted earnings per share was KRW 38 compared to diluted loss per share of KRW 126 a year ago.
SAMIL PHARMACEUTICAL CO., LTD is a Korea-based company mainly engaged in the manufacture of medicines. The Companyâs products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The Company distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.
SAMIL PHARMACEUTICAL CO.,LTD 
